Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$209.10
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,051,977,216.00
EPSttm : 6.68
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$209.10
1.43%
$2.94

Float Short %

11.56

Margin Of Safety %

-7

Put/Call OI Ratio

1.74

EPS Next Q Diff

EPS Last/This Y

2.74

EPS This/Next Y

2.76

Price

205.88

Target Price

222.45

Analyst Recom

1.17

Performance Q

40.92

Relative Volume

0.54

Beta

0.49

Ticker: KRYS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20KRYS195.962.077.528070
2025-10-21KRYS190.762.520.429957
2025-10-22KRYS186.212.510.269962
2025-10-23KRYS186.182.500.299975
2025-10-24KRYS186.182.491.409979
2025-10-27KRYS190.22.4924.679980
2025-10-28KRYS189.692.475.009940
2025-10-29KRYS184.812.480.259951
2025-10-30KRYS188.952.470.389958
2025-10-31KRYS196.992.4610.679964
2025-11-03KRYS198.52.452.6210806
2025-11-04KRYS203.272.360.0510903
2025-11-05KRYS199.881.740.0712129
2025-11-06KRYS199.681.700.5912214
2025-11-07KRYS197.751.700.0312227
2025-11-10KRYS199.591.711.0012206
2025-11-11KRYS2031.710.0512207
2025-11-12KRYS203.151.741.1812128
2025-11-13KRYS201.431.740.0612131
2025-11-14KRYS206.161.740.3412137
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20KRYS195.96-13.0190.14.95
2025-10-21KRYS190.51-13.0168.44.95
2025-10-22KRYS186.42-13.0170.24.95
2025-10-23KRYS186.28-13.0178.54.95
2025-10-24KRYS186.20-13.0178.34.95
2025-10-27KRYS190.05-13.0186.84.95
2025-10-28KRYS189.65-13.0178.35.08
2025-10-29KRYS185.00-13.0169.65.08
2025-10-30KRYS189.08-13.0187.35.08
2025-10-31KRYS197.51-13.0196.25.08
2025-11-03KRYS197.66-13.0179.15.08
2025-11-04KRYS203.04-13.0188.55.08
2025-11-05KRYS199.80-13.0172.45.08
2025-11-06KRYS199.68-18.5216.75.12
2025-11-07KRYS197.930.7212.75.12
2025-11-10KRYS199.530.7220.45.12
2025-11-11KRYS203.0013.1224.25.86
2025-11-12KRYS203.2013.1217.45.86
2025-11-13KRYS201.4313.1213.75.86
2025-11-14KRYS205.8813.1226.75.86
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20KRYS-2.390.9113.69
2025-10-21KRYS-2.390.9113.69
2025-10-22KRYS-2.390.9113.69
2025-10-23KRYS-2.390.9113.69
2025-10-24KRYS-2.390.9113.69
2025-10-27KRYS-2.39-0.4411.62
2025-10-28KRYS-2.39-0.4411.62
2025-10-29KRYS-2.39-0.4411.62
2025-10-30KRYS-2.39-0.4411.62
2025-10-31KRYS-2.39-0.4411.62
2025-11-03KRYS-2.39-0.3811.62
2025-11-04KRYS-2.39-0.3811.62
2025-11-05KRYS-2.39-0.3811.62
2025-11-06KRYS-2.39-0.3811.60
2025-11-07KRYS-2.39-0.3811.60
2025-11-10KRYS-2.39-0.5811.60
2025-11-11KRYS-2.39-0.5811.60
2025-11-12KRYS-2.39-0.5811.57
2025-11-13KRYS-2.39-0.5811.57
2025-11-14KRYS-2.39-0.5811.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.73

Avg. EPS Est. Next Quarter

1.46

Insider Transactions

-2.39

Institutional Transactions

-0.58

Beta

0.49

Average Sales Estimate Current Quarter

107

Average Sales Estimate Next Quarter

120

Fair Value

190.72

Quality Score

88

Growth Score

40

Sentiment Score

31

Actual DrawDown %

6.1

Max Drawdown 5-Year %

-53.4

Target Price

222.45

P/E

30.92

Forward P/E

27.01

PEG

0.62

P/S

16.02

P/B

5.25

P/Free Cash Flow

36.1

EPS

6.67

Average EPS Est. Cur. Y​

5.86

EPS Next Y. (Est.)

8.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

0.54

Return on Equity vs Sector %

-12.8

Return on Equity vs Industry %

2

EPS 1 7Days Diff

0.8

EPS 1 30Days Diff

0.93

EBIT Estimation

226.7
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading